Chronic Pain
Chronic pain is increasingly recognised as a multifaceted condition that may respond to psychedelic therapies, which are gaining attention in clinical settings for their potential efficacy in pain management. Recent research indicates that compounds such as psilocybin and MDMA are entering clinical trials aimed at exploring their therapeutic effects on chronic pain syndromes.
What is Chronic Pain?
Chronic pain is a complex and often debilitating condition characterised by persistent pain lasting longer than the usual course of acute illness, often exceeding three months. It can arise from various underlying pathological conditions, including injury, inflammation, and nerve damage.
The pathophysiology of chronic pain involves alterations in the nervous system, including central sensitisation, where the nervous system becomes hyper-responsive to stimuli, leading to the amplification of pain signals. Symptoms can include not only physical discomfort but also psychological effects such as anxiety and depression.
Chronic pain conditions can manifest in various forms, including neuropathic pain, fibromyalgia, and chronic lower back pain, each requiring tailored treatment approaches. Patients often report reduced quality of life due to the constant discomfort and associated emotional distress.
Current Treatments
Standard treatments for chronic pain generally include pharmacological options such as nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, antidepressants, and physical therapy, alongside psychological therapies like cognitive behavioural therapy (CBT).
Psychedelic Effect Matrix
Systematic comparison of compound efficacy and evidence levels for Chronic Pain.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| Psilocybin Multiple clinical trials have shown significant pain reduction in conditions like neuropathic pain and fibromyalgia. | Large | High | Consistent |
| MDMA Preliminary studies suggest MDMA can provide relief by addressing psychological components of chronic pain. | Medium | Moderate | Consistent |
| Ketamine Widely recognised for its rapid effects on pain relief, particularly in treatment-resistant chronic pain conditions. | Large | High | High |
Psilocybin and Chronic Pain
Clinical studies have also highlighted psilocybin’s potential to reduce rumination and anxiety levels, improving patients’ quality of life and pain thresholds. Positive outcomes have been observed in patients coping with cancer-related pain and other chronic pain syndromes.
MDMA and Chronic Pain
Emerging evidence suggests MDMA may reduce anxiety levels and improve coping mechanisms, thereby alleviating the pain experience. Trial results indicate a promising role for MDMA as part of a holistic treatment approach for chronic pain.
Key Insights
- 1
Psychedelic therapies are being explored as adjuncts to standard treatments for chronic pain, showing promising initial results.
- 2
Psilocybin and MDMA have advanced to clinical trials, demonstrating safety and potential efficacy in specific chronic pain conditions.
- 3
Research suggests that psychedelics may facilitate improved mental health outcomes, potentially enhancing pain tolerance and reducing the perception of pain.
Industrial Landscape
Key players in psychedelic research for chronic pain include academic institutions like Johns Hopkins University, non-profit organisations focusing on psychedelic therapy, and various pharmaceutical companies investing in psychedelic drug development.
Quick Indicators
\"Ongoing clinical evaluations are investigating Chronic Pain as a primary indication for various psychedelic compounds.\"
Key Organizations
4 ConnectedDelix Therapeutics
Delix Therapeutics is harnessing the power of neuroplastogens, a novel class of compounds designed to bring about a new paradigm in brain health therapeutics with treatments intended to be safe, fast-acting, and long-lasting. Through its discovery platform, Delix has identified non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. The company was co-founded in 2019 by David E. Olson and Nick Haft, building upon Olson's discovery at the University of California, Davis, of several novel psychoplastogens that have significant therapeutic potential in preclinical models, without hallucinogenic side effects. Delix's treatments are designed to address the root cause of neuropsychiatric conditions by repairing the underlying synaptic damage through targeted neuroplasticity. To date, the company has synthesized over 2000 novel psychoplastogens, many of which are analogs of known psychedelics such as ibogaine and 5-MeO-DMT. Their lead compound, zalsupindole (DLX-001), produces the same rapid and sustained structural and functional plasticity as ketamine, psilocybin, and DMT, without inducing hallucinations or dissociation. Recent Phase I data have demonstrated that DLX-001 is associated with robust signs of CNS engagement and a favorable safety and tolerability profile, with no serious adverse events reported to date. The company's compounds are tailored for swift neuronal repair and can be taken at-home, providing significant advantages to patients, their loved ones, and healthcare providers. Delix focuses on developing non-hallucinogenic psychoplastogens as scalable alternatives to first-generation hallucinogenic psychoplastogens like ketamine and psilocybin.
MAPS
The description of the stakeholder
Lykos Therapeutics
Longer description of Lykos .. lorem ipsum ..
Leiden University
Leiden University doesn't have a dedicated research centre for psychedelics. However, several staff members from their medical centre and psychology faculty are working with psychedelics. Researchers here are working with other universities including Utrecht University as well as Compass Pathways.
Prominent Researchers
1 LinkedConnected Evidence
The latest clinical data points and verified academic findings associated with Chronic Pain.